Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C.

JAMA Oncol. 2018 Feb 1;4(2):196-202. doi: 10.1001/jamaoncol.2017.4218.

PMID:
29242937
2.

High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.

Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK.

Gynecol Oncol. 2017 Aug;146(2):247-253. doi: 10.1016/j.ygyno.2017.05.017. Epub 2017 May 19.

3.

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.

Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.

Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049.

4.

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Rose PG, Java JJ, Morgan MA, Alvarez-Secord A, Kesterson JP, Stehman FB, Warshal DP, Creasman WT, Hanjani P, Morris RT, Copeland LJ.

Gynecol Oncol. 2016 Dec;143(3):511-515. doi: 10.1016/j.ygyno.2016.09.005. Epub 2016 Sep 28.

5.

Five-Day Intravascular Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial.

Yarandi F, Mousavi A, Abbaslu F, Aminimoghaddam S, Nekuie S, Adabi K, Hanjani P.

Int J Gynecol Cancer. 2016 Jun;26(5):971-6. doi: 10.1097/IGC.0000000000000687.

PMID:
27101581
6.

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ 2nd, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF.

Gynecol Oncol. 2016 Apr;141(1):43-8. doi: 10.1016/j.ygyno.2016.02.025.

7.

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE.

Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497. Epub 2014 Oct 7.

8.

A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.

Duska LR, Blessing JA, Rotmensch J, Mannel RS, Hanjani P, Rose PG, Dizon DS.

Gynecol Oncol. 2014 Oct;135(1):44-8. doi: 10.1016/j.ygyno.2014.07.101. Epub 2014 Aug 1.

9.

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

Campos SM, Brady WE, Moxley KM, O'Cearbhaill RE, Lee PS, DiSilvestro PA, Rotmensch J, Rose PG, Thaker PH, O'Malley DM, Hanjani P, Zuna RE, Hensley ML.

Gynecol Oncol. 2014 Jun;133(3):537-41. doi: 10.1016/j.ygyno.2014.02.036. Epub 2014 Mar 1. Erratum in: Gynecol Oncol. 2014 Dec;135(3):624.

10.

Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.

Fleming GF, Filiaci VL, Marzullo B, Zaino RJ, Davidson SA, Pearl M, Makker V, Burke JJ 2nd, Zweizig SL, Van Le L, Hanjani P, Downey G, Walker JL, Reyes HD, Leslie KK.

Gynecol Oncol. 2014 Mar;132(3):585-92. doi: 10.1016/j.ygyno.2014.01.015. Epub 2014 Jan 20.

11.

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ.

Gynecol Oncol. 2013 Jun;129(3):486-94. doi: 10.1016/j.ygyno.2013.02.019. Epub 2013 Feb 21.

12.

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK.

Gynecol Oncol. 2013 Apr;129(1):86-91. doi: 10.1016/j.ygyno.2013.01.006. Epub 2013 Jan 13.

13.

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG.

Gynecol Oncol. 2012 Nov;127(2):345-50. doi: 10.1016/j.ygyno.2012.07.127. Epub 2012 Aug 7.

14.

A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.

McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, Rubin SC, Rose PG, Small L, Benbrook DM.

Gynecol Oncol. 2012 Nov;127(2):356-61. doi: 10.1016/j.ygyno.2012.07.095. Epub 2012 Jul 14.

PMID:
22796461
15.

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK.

J Clin Oncol. 2011 Jun 1;29(16):2259-65. doi: 10.1200/JCO.2010.32.6397. Epub 2011 May 2.

16.

A randomized phase III trial of IV carboplatin and paclitaxel √ó 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.

Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H.

Gynecol Oncol. 2011 Jul;122(1):89-94. doi: 10.1016/j.ygyno.2011.03.013. Epub 2011 May 6.

17.

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.

Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK.

Gynecol Oncol. 2011 Jun 1;121(3):455-61. doi: 10.1016/j.ygyno.2011.02.013. Epub 2011 Mar 17.

18.

Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.

Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, De Geest K, Bonebrake AJ, Walker JL.

Gynecol Oncol. 2011 Mar;120(3):459-63. doi: 10.1016/j.ygyno.2010.11.012. Epub 2010 Dec 7.

PMID:
21144560
19.

Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, Miller BE, Susumu N, Ueland FR.

J Clin Oncol. 2010 Jun 1;28(16):2727-31. doi: 10.1200/JCO.2009.26.8326. Epub 2010 Apr 26.

20.

Evaluation of two management strategies for preoperative grade I endometrial cancer.

Hanjani P.

Obstet Gynecol. 2009 Nov;114(5):1146; author reply 1146-7. doi: 10.1097/AOG.0b013e3181bf3272. No abstract available.

PMID:
20168122
21.

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH.

J Clin Oncol. 2009 Jun 1;27(16):2686-91. doi: 10.1200/JCO.2008.19.2963. Epub 2009 Mar 30.

22.

Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.

Farley J, Fuchiuji S, Darcy KM, Tian C, Hoskins WJ, McGuire WP, Hanjani P, Warshal D, Greer BE, Belinson J, Birrer MJ.

Gynecol Oncol. 2009 Jun;113(3):341-7. doi: 10.1016/j.ygyno.2009.02.009. Epub 2009 Mar 9.

PMID:
19272639
23.

Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia.

Yarandi F, Eftekhar Z, Shojaei H, Kanani S, Sharifi A, Hanjani P.

Int J Gynaecol Obstet. 2008 Oct;103(1):33-7. doi: 10.1016/j.ijgo.2008.05.013. Epub 2008 Jul 16.

PMID:
18632105
24.

Successful treatment of two patients with gestational trophoblastic neoplasm presenting with emergent neurologic symptoms.

Ghaemmaghami F, Behtash N, Ayatollahi H, Hanjani P.

Int J Gynecol Cancer. 2006 Mar-Apr;16(2):937-40.

PMID:
16681792
25.

Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.

Brewer CA, Blessing JA, Nagourney RA, Morgan M, Hanjani P.

Gynecol Oncol. 2006 Nov;103(2):446-50. Epub 2006 Apr 27.

PMID:
16643994
26.

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.

Gynecologic Oncology Group, Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S.

Gynecol Oncol. 2006 Jun;101(3):436-40. Epub 2005 Dec 2.

PMID:
16325893
27.

Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia.

Gilani MM, Yarandi F, Eftekhar Z, Hanjani P.

Aust N Z J Obstet Gynaecol. 2005 Apr;45(2):161-4.

PMID:
15760322
28.

Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.

Sutton G, Blessing J, Hanjani P, Kramer P; Gynecologic Oncology Group.

Gynecol Oncol. 2005 Mar;96(3):749-52.

PMID:
15721421
29.

A case-control study to evaluate urinary tract complications in radical hysterectomy.

Behtash N, Ghaemmaghami F, Ayatollahi H, Khaledi H, Hanjani P.

World J Surg Oncol. 2005 Feb 16;3(1):12.

30.

Evaluation and management of brain metastatic patients with high-risk gestational trophoblastic tumors.

Ghaemmaghami F, Behtash N, Memarpour N, Soleimani K, Hanjani P, Hashemi FA.

Int J Gynecol Cancer. 2004 Sep-Oct;14(5):966-71.

PMID:
15361210
31.

Management of patients with metastatic gestational trophoblastic tumor.

Ghaemmaghami F, Behtash N, Soleimani K, Hanjani P.

Gynecol Oncol. 2004 Jul;94(1):187-90.

PMID:
15262140
32.

Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study.

Burger RA, Darcy KM, DiSaia PJ, Monk BJ, Grosen EA, Gatanaga T, Granger GA, Wang J, Tian C, Hanjani P, Cohn DE.

Cancer. 2004 Jul 1;101(1):106-15.

33.

EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV).

Ghaemmaghami F, Modares M, Arab M, Behtash N, Moosavi AZ, Khanafshar N, Hanjani P.

Int J Gynecol Cancer. 2004 Mar-Apr;14(2):360-5.

PMID:
15086738
34.

Borderline ovarian tumours: clinical analysis of 38 cases.

Behtash N, Modares M, Abolhasani M, Ghaemmaghami F, Mousavi M, Yarandi F, Hanjani P.

J Obstet Gynaecol. 2004 Feb;24(2):157-60.

PMID:
14766453
35.

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W; Gynecologic Oncology Group study.

Gynecol Oncol. 2004 Jan;92(1):10-4.

PMID:
14751131
36.

Embryonal rhabdomyosarcoma of the uterine cervix: case report and review of the literature.

Behtash N, Mousavi A, Tehranian A, Khanafshar N, Hanjani P.

Gynecol Oncol. 2003 Nov;91(2):452-5. Review.

PMID:
14599884
37.

Simple hysterectomy in the presence of invasive cervical cancer in Iran.

Behtash N, Mousavi A, Mohit M, Modares M, Khanafshar N, Hanjani P.

Int J Gynecol Cancer. 2003 Mar-Apr;13(2):177-81.

PMID:
12657120
38.

To peritonealise or not to peritonealise? A randomised trial at abdominal hysterectomy in Iran.

Behtash N, Ghaemaghami F, Gilani MM, Rajabi MT, Moghimi R, Hanjani P.

J Obstet Gynaecol. 2001 Sep;21(5):520-4. Retraction in: MacLean A, Petrylak A. J Obstet Gynaecol. 2010 Feb;30(2):221.

PMID:
12521812
39.

Uterine papillary serous carcinoma after pelvic radiation therapy for cancer of the cervix.

Behtash N, Tehranian A, Ardalan FA, Hanjani P.

J Obstet Gynaecol. 2002 Jan;22(1):96-7.

PMID:
12521747
40.

Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.

Hanjani P, Nolte S, Shahin MS.

Gynecol Oncol. 2002 May;85(2):278-84.

PMID:
11972388
41.

BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.

Smith SA, Richards WE, Caito K, Hanjani P, Markman M, DeGeest K, Gallion HH.

Gynecol Oncol. 2001 Dec;83(3):586-92.

PMID:
11733976
42.

Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.

Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW, Hanjani P, Kristensen G, Malfetano JH, Beckman RA, Ross GA, Lane SR, DeWitte MH, Fields SZ.

J Clin Oncol. 2001 Oct 1;19(19):3967-75.

PMID:
11579118
43.

Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.

Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA.

Gynecol Oncol. 2000 Jun;77(3):446-9.

PMID:
10831357
44.

Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.

Markman M, Blessing JA, Alvarez RD, Hanjani P, Waggoner S, Hall K.

Gynecol Oncol. 2000 Apr;77(1):112-5.

PMID:
10739699
45.

Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.

Berek JS, Markman M, Blessing JA, Kucera PR, Nelson BE, Anderson B, Hanjani P.

Gynecol Oncol. 1999 Jul;74(1):48-52.

PMID:
10385550
46.

Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.

Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC.

J Clin Oncol. 1998 Aug;16(8):2620-4.

PMID:
9704711
47.

Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group.

Williams S, Blessing JA, Liao SY, Ball H, Hanjani P.

J Clin Oncol. 1994 Apr;12(4):701-6.

PMID:
7512129
48.
49.

Echinomycin (NSC 526417) in recurrent and metastatic nonsquamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.

Muss HB, Blessing JA, Hanjani P, Malfetano JH, Kemp GM, Webster K.

Am J Clin Oncol. 1992 Aug;15(4):363-4.

PMID:
1325110
50.

Telephone counseling improves adherence to colposcopy among lower-income minority women.

Lerman C, Hanjani P, Caputo C, Miller S, Delmoor E, Nolte S, Engstrom P.

J Clin Oncol. 1992 Feb;10(2):330-3.

PMID:
1732434

Supplemental Content

Loading ...
Support Center